PE20130217A1 - Composiciones farmaceuticas y metodos para su elaboracion - Google Patents
Composiciones farmaceuticas y metodos para su elaboracionInfo
- Publication number
- PE20130217A1 PE20130217A1 PE2012002115A PE2012002115A PE20130217A1 PE 20130217 A1 PE20130217 A1 PE 20130217A1 PE 2012002115 A PE2012002115 A PE 2012002115A PE 2012002115 A PE2012002115 A PE 2012002115A PE 20130217 A1 PE20130217 A1 PE 20130217A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- amount
- preparation
- methods
- pharmaceutical compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 238000010979 pH adjustment Methods 0.000 abstract 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 abstract 1
- 229960000639 pazopanib Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33171510P | 2010-05-05 | 2010-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130217A1 true PE20130217A1 (es) | 2013-03-21 |
Family
ID=44851507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002115A PE20130217A1 (es) | 2010-05-05 | 2011-05-05 | Composiciones farmaceuticas y metodos para su elaboracion |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20120028918A1 (enExample) |
| EP (1) | EP2566331B1 (enExample) |
| JP (1) | JP5835717B2 (enExample) |
| KR (1) | KR20130071434A (enExample) |
| CN (1) | CN102970871A (enExample) |
| AR (1) | AR081364A1 (enExample) |
| AU (1) | AU2011247995B2 (enExample) |
| BR (1) | BR112012028291A2 (enExample) |
| CA (1) | CA2798386A1 (enExample) |
| CL (1) | CL2012003075A1 (enExample) |
| CO (1) | CO6640262A2 (enExample) |
| CR (1) | CR20120556A (enExample) |
| DO (1) | DOP2012000281A (enExample) |
| EA (1) | EA201291168A1 (enExample) |
| ES (1) | ES2519615T3 (enExample) |
| IL (1) | IL222751A0 (enExample) |
| MA (1) | MA34286B1 (enExample) |
| MX (1) | MX2012012837A (enExample) |
| NZ (1) | NZ603411A (enExample) |
| PE (1) | PE20130217A1 (enExample) |
| PH (1) | PH12012502159A1 (enExample) |
| SG (1) | SG185087A1 (enExample) |
| TW (1) | TW201206908A (enExample) |
| UY (1) | UY33367A (enExample) |
| WO (1) | WO2011140343A1 (enExample) |
| ZA (1) | ZA201208265B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| AR081364A1 (es) * | 2010-05-05 | 2012-08-29 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion |
| WO2012019136A2 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision 4, Inc. | Injector apparatus and method for drug delivery |
| AU2011329656B2 (en) | 2010-11-19 | 2017-01-05 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| SI2755600T1 (sl) | 2011-09-16 | 2021-08-31 | Forsight Vision4, Inc. | Naprava za izmenjavo tekočine |
| JP2015507020A (ja) * | 2012-02-17 | 2015-03-05 | ファーマサイクリックス，インク． | ヒストンデアセチラーゼ阻害剤とパゾパニブの組み合わせおよびその使用 |
| US9629021B2 (en) * | 2012-03-08 | 2017-04-18 | Samsung Electronics Co., Ltd | Method for controlling service in radio communication system |
| AU2014236455B2 (en) * | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| AU2014241163B2 (en) | 2013-03-28 | 2018-09-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
| JP6612232B2 (ja) | 2013-08-28 | 2019-11-27 | クラウン バイオサイエンス インコーポレイテッド（タイカン） | 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用 |
| MY182793A (en) * | 2014-08-08 | 2021-02-05 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| JP7037360B2 (ja) | 2014-11-10 | 2022-03-16 | フォーサイト・ビジョン フォー・インコーポレーテッド | 拡張可能な薬物送達デバイス |
| WO2016104690A1 (ja) | 2014-12-25 | 2016-06-30 | 国立大学法人京都大学 | 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー |
| BR112018070383A2 (pt) | 2016-04-05 | 2019-02-05 | Forsight Vision4 Inc | dispositivos para aplicação de fármaco oculares implantáveis |
| WO2018192416A1 (en) * | 2017-04-17 | 2018-10-25 | National Institute Of Biological Sciences, Beijing | Treating Male Senescence |
| US11174253B2 (en) | 2017-08-02 | 2021-11-16 | Alphala Co., Ltd. | Compound and pharmaceutical composition containing the same |
| SI3810089T1 (sl) * | 2018-06-07 | 2023-11-30 | Pfizer Inc. | Vodna formulacija,ki vsebuje 1-(4-((4-(dimetilamino)piperidin-1-il)karbonil)fenil)-3-(4-(4,6- dimorfolin-4-il-1,3,5-triazin-2-il)fenil)sečnino |
| CN113350351A (zh) * | 2020-03-13 | 2021-09-07 | 青晓制药公司 | 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用 |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
| US20240050429A1 (en) * | 2022-08-10 | 2024-02-15 | Qx Therapeutics, Inc. | Pazopanib pharmaceutical composition, injection and preparation method and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8904296D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
| US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| PL1968594T3 (pl) * | 2005-11-29 | 2011-03-31 | Glaxosmithkline Llc | Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| WO2007121483A2 (en) * | 2006-04-18 | 2007-10-25 | Ekr Therapeutics, Inc. | Pre-mixed, ready-to-use iv bolus compositions and methods of use |
| MX2010004281A (es) * | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
| CA2711759A1 (en) * | 2008-01-30 | 2009-08-06 | Genentech, Inc. | Pyrazolopyrimidine pi3k inhibitor compounds and methods of use |
| CN102573477A (zh) * | 2009-07-16 | 2012-07-11 | 葛兰素惠尔康制造业私人有限公司 | 治疗方法 |
| US20120232102A1 (en) * | 2009-09-30 | 2012-09-13 | Chun-Fang Xu | Methods Of Administration And Treatment |
| UY33164A (es) * | 2010-01-06 | 2011-08-31 | Glaxo Wellcome Mfg Pte Ltd | Metodo de tratamiento |
| US20130023550A1 (en) * | 2010-05-05 | 2013-01-24 | Glaxo Wellcome Manufacturing Pte, Ltd | Pharmaceutical compositions and methods of making same |
| AR081364A1 (es) * | 2010-05-05 | 2012-08-29 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion |
-
2011
- 2011-05-03 AR ARP110101514A patent/AR081364A1/es unknown
- 2011-05-03 UY UY0001033367A patent/UY33367A/es unknown
- 2011-05-03 TW TW100115488A patent/TW201206908A/zh unknown
- 2011-05-05 MX MX2012012837A patent/MX2012012837A/es active IP Right Grant
- 2011-05-05 CA CA2798386A patent/CA2798386A1/en not_active Abandoned
- 2011-05-05 CN CN2011800333447A patent/CN102970871A/zh active Pending
- 2011-05-05 EA EA201291168A patent/EA201291168A1/ru unknown
- 2011-05-05 MA MA35417A patent/MA34286B1/fr unknown
- 2011-05-05 NZ NZ603411A patent/NZ603411A/en not_active IP Right Cessation
- 2011-05-05 ES ES11778348.0T patent/ES2519615T3/es active Active
- 2011-05-05 EP EP11778348.0A patent/EP2566331B1/en active Active
- 2011-05-05 BR BR112012028291A patent/BR112012028291A2/pt not_active IP Right Cessation
- 2011-05-05 KR KR1020127031739A patent/KR20130071434A/ko not_active Withdrawn
- 2011-05-05 US US13/133,030 patent/US20120028918A1/en not_active Abandoned
- 2011-05-05 PE PE2012002115A patent/PE20130217A1/es not_active Application Discontinuation
- 2011-05-05 AU AU2011247995A patent/AU2011247995B2/en not_active Ceased
- 2011-05-05 WO PCT/US2011/035363 patent/WO2011140343A1/en not_active Ceased
- 2011-05-05 SG SG2012079968A patent/SG185087A1/en unknown
- 2011-05-05 PH PH1/2012/502159A patent/PH12012502159A1/en unknown
- 2011-05-05 JP JP2013509268A patent/JP5835717B2/ja not_active Expired - Fee Related
- 2011-05-05 US US13/101,689 patent/US20110281901A1/en not_active Abandoned
-
2012
- 2012-10-29 IL IL222751A patent/IL222751A0/en unknown
- 2012-10-31 CL CL2012003075A patent/CL2012003075A1/es unknown
- 2012-11-01 CR CR20120556A patent/CR20120556A/es unknown
- 2012-11-02 ZA ZA2012/08265A patent/ZA201208265B/en unknown
- 2012-11-02 DO DO2012000281A patent/DOP2012000281A/es unknown
- 2012-12-05 CO CO12221016A patent/CO6640262A2/es not_active Application Discontinuation
-
2015
- 2015-05-06 US US14/705,298 patent/US20150231265A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| UY33367A (es) | 2011-10-31 |
| HK1175947A1 (en) | 2013-07-19 |
| DOP2012000281A (es) | 2013-05-31 |
| CO6640262A2 (es) | 2013-03-22 |
| AU2011247995B2 (en) | 2014-07-31 |
| CL2012003075A1 (es) | 2013-03-08 |
| BR112012028291A2 (pt) | 2015-09-15 |
| IL222751A0 (en) | 2012-12-31 |
| AR081364A1 (es) | 2012-08-29 |
| US20110281901A1 (en) | 2011-11-17 |
| EP2566331B1 (en) | 2014-09-03 |
| PH12012502159A1 (en) | 2013-02-04 |
| AU2011247995A1 (en) | 2012-12-13 |
| CN102970871A (zh) | 2013-03-13 |
| CA2798386A1 (en) | 2011-11-10 |
| EA201291168A1 (ru) | 2013-06-28 |
| CR20120556A (es) | 2013-02-20 |
| TW201206908A (en) | 2012-02-16 |
| KR20130071434A (ko) | 2013-06-28 |
| JP2013525501A (ja) | 2013-06-20 |
| NZ603411A (en) | 2014-10-31 |
| EP2566331A4 (en) | 2013-09-18 |
| SG185087A1 (en) | 2012-12-28 |
| MX2012012837A (es) | 2013-01-24 |
| ZA201208265B (en) | 2013-07-31 |
| ES2519615T3 (es) | 2014-11-07 |
| EP2566331A1 (en) | 2013-03-13 |
| US20120028918A1 (en) | 2012-02-02 |
| MA34286B1 (fr) | 2013-06-01 |
| US20150231265A1 (en) | 2015-08-20 |
| WO2011140343A1 (en) | 2011-11-10 |
| JP5835717B2 (ja) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081364A1 (es) | Composiciones farmaceuticas de pazopanib y metodos para su elaboracion | |
| AR089673A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| AR089372A1 (es) | Composiciones de cuidado oral | |
| BR122020001787A8 (pt) | Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| BR112015004984A2 (pt) | formulações aquosas estáveis de adalimumab | |
| AR084285A1 (es) | Composiciones inmunogenicas | |
| NI201300068A (es) | Moduladores del receptor de glucagón | |
| AR083034A1 (es) | ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO | |
| CL2013002810A1 (es) | Composicion farmaceutica solida oral que comprende a) un compuesto 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol (fingolimod) en una cantidad de 0,5 mg o menos, o una sal del mismo, b) un relleno y c) un estabilizante que comprende una ciclodextrina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple. | |
| ECSP14013200A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| AR081870A1 (es) | Composicion farmaceutica que comprende un derivado de amida o sal farmaceuticamente aceptable del mismo | |
| AR087371A1 (es) | Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos | |
| BR112012022469A2 (pt) | composição amaciante de tecido concentrada líquida. | |
| AR076932A1 (es) | Formulaciones de n-halamina con actividad antimicrobiana aumentada. comprimido desinfectante. metodo para desinfectar. | |
| BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
| BR112014004732A2 (pt) | composto benzotiazolona | |
| AR089122A1 (es) | Formulaciones orales para tratar la sobrecarga de metales | |
| AR086045A1 (es) | Componente de formulacion | |
| ECSP11010998A (es) | Formulación galénica que comprende alisquireno y proceso para su preparación mediante granulación de extrusión fundida | |
| NZ603783A (en) | Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant | |
| AR103719A1 (es) | Composición líquida tópica para el lavado intrauterino que contiene melatonina | |
| AR068978A1 (es) | N-oxidos de venlafaxina y o-desmetilvenlafaxina como prodrogas | |
| CL2013003137A1 (es) | Composición farmacéutica líquida oral que contiene divalproex sódico (2-15 % p/v de la composición), y uno o más excipientes, cuyo ph es mayor a 6; procedimiento de preparación de la composición que comprende: (a) mezclar hidróxido de sodio en agua purificada, (b) añadir divalproex sódico y excipientes; y (c) ajustar ph sobre 6. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |